2. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for
response and minimal residual disease assessment in multiple myeloma. The lancet oncology.
2016;17(8):e328-346.
3. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD
negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv.
2020;4(23):5988-5999.
4. Jackson GH, Davies FE, Pawlyn C, et al. Response-adapted intensification with cyclophosphamide,
bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple
myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol.
2019;6(12):e616-e629.
5. Goldschmidt H, Mai EK, Durig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed
myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34(7):1853-1865.
6. Avet-Loiseau H, Ludwig H, Landgren O, et al. Minimal Residual Disease Status as a Surrogate Endpoint
for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clin
Lymphoma Myeloma Leuk. 2020;20(1):e30-e37.
7. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing
is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456-2464.
8. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and
dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood.
2020;136(8):936-945.
9. Ho C, Syed M, Roshal M, et al. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-
Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-
Sensitivity Flow Cytometry. J Mol Diagn. 2021;23(2):181-199.
10. Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus
recommendations on imaging in monoclonal plasma cell disorders. The lancet oncology.
2019;20(6):e302-e312.
11. Moreau P, Attal M, Caillot D, et al. Prospective Evaluation of Magnetic Resonance Imaging and
(18)FFluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and
Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the
IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017;35(25):2911-2918